ARDX — ARDELYX, INC. catalysts
Next verified catalyst
2026-09-01 — Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patie · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-01 in 26d
ESTIMATED |
READOUT
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pedia
Phase 3 · Irritable Bowel Syndrome With Constipation (IBS-C) |
ARDX ARDELYX, INC. | Tenapanor 50 MG, Tenapanor 25 mg bid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|